CN102260322A - 幽门螺杆菌抗原肽及其应用 - Google Patents
幽门螺杆菌抗原肽及其应用 Download PDFInfo
- Publication number
- CN102260322A CN102260322A CN201110188650XA CN201110188650A CN102260322A CN 102260322 A CN102260322 A CN 102260322A CN 201110188650X A CN201110188650X A CN 201110188650XA CN 201110188650 A CN201110188650 A CN 201110188650A CN 102260322 A CN102260322 A CN 102260322A
- Authority
- CN
- China
- Prior art keywords
- seq
- aminoacid sequence
- antibody
- antigen
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 119
- 108091007433 antigens Proteins 0.000 title claims abstract description 87
- 102000036639 antigens Human genes 0.000 title claims abstract description 85
- 239000000427 antigen Substances 0.000 title claims abstract description 82
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 44
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 42
- 229920001184 polypeptide Polymers 0.000 claims abstract description 32
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 21
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 21
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 21
- 150000001413 amino acids Chemical class 0.000 claims description 84
- 108010046334 Urease Proteins 0.000 claims description 36
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 12
- 241000589989 Helicobacter Species 0.000 claims description 10
- 108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 claims description 8
- 210000001187 pylorus Anatomy 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 21
- 239000000203 mixture Substances 0.000 abstract description 37
- 229960005486 vaccine Drugs 0.000 abstract description 26
- 230000001681 protective effect Effects 0.000 abstract description 20
- 108010001160 IgY Proteins 0.000 description 59
- 238000012360 testing method Methods 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 38
- 210000002969 egg yolk Anatomy 0.000 description 36
- 238000001514 detection method Methods 0.000 description 34
- 101710116435 Outer membrane protein Proteins 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 26
- 102000016938 Catalase Human genes 0.000 description 24
- 108010053835 Catalase Proteins 0.000 description 24
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 24
- 229940023146 nucleic acid vaccine Drugs 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 23
- 101710194807 Protective antigen Proteins 0.000 description 22
- 210000003296 saliva Anatomy 0.000 description 22
- 239000006228 supernatant Substances 0.000 description 20
- 239000007788 liquid Substances 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 241000287828 Gallus gallus Species 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 230000036039 immunity Effects 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 238000002156 mixing Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 241001026509 Kata Species 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 101150061086 ureB gene Proteins 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 235000013601 eggs Nutrition 0.000 description 9
- 101150115163 katA gene Proteins 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 230000002285 radioactive effect Effects 0.000 description 9
- 101100059196 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) katE gene Proteins 0.000 description 8
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 229910052737 gold Inorganic materials 0.000 description 8
- 101150013110 katG gene Proteins 0.000 description 8
- 101150108683 katG2 gene Proteins 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 229960004756 ethanol Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000004816 latex Substances 0.000 description 6
- 229920000126 latex Polymers 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241001168604 Helicobacter pylori NCTC 11639 Species 0.000 description 5
- 101710110284 Nuclear shuttle protein Proteins 0.000 description 5
- 206010057249 Phagocytosis Diseases 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000008782 phagocytosis Effects 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 102000013566 Plasminogen Human genes 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- 102100022647 Reticulon-1 Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 229940031551 inactivated vaccine Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010019375 Helicobacter infections Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241001045988 Neogene Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940031567 attenuated vaccine Drugs 0.000 description 3
- 238000007622 bioinformatic analysis Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000024835 cytogamy Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 101150091879 neo gene Proteins 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000710190 Cardiovirus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 description 2
- 101710144127 Non-structural protein 1 Proteins 0.000 description 2
- 101710144128 Non-structural protein 2 Proteins 0.000 description 2
- 101710144111 Non-structural protein 3 Proteins 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100022648 Reticulon-2 Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102100031776 SH2 domain-containing protein 3A Human genes 0.000 description 2
- 102100021798 SH2 domain-containing protein 3C Human genes 0.000 description 2
- 102100031056 Serine protease 57 Human genes 0.000 description 2
- 101710197596 Serine protease 57 Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000012092 latex agglutination test Methods 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010014096 Echinococciasis Diseases 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001473949 Helicobacter pylori NCTC 11637 = CCUG 17874 = ATCC 43504 Species 0.000 description 1
- 241001473947 Helicobacter pylori SS1 Species 0.000 description 1
- 108700010014 Helicobacter pylori katA Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100451434 Mus musculus Hp gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 206010050208 Teratospermia Diseases 0.000 description 1
- 208000002312 Teratozoospermia Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000003037 histogenic effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110188650.XA CN102260322B (zh) | 2011-07-06 | 2011-07-06 | 幽门螺杆菌抗原肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110188650.XA CN102260322B (zh) | 2011-07-06 | 2011-07-06 | 幽门螺杆菌抗原肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102260322A true CN102260322A (zh) | 2011-11-30 |
CN102260322B CN102260322B (zh) | 2014-04-23 |
Family
ID=45007181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110188650.XA Active CN102260322B (zh) | 2011-07-06 | 2011-07-06 | 幽门螺杆菌抗原肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102260322B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103961704A (zh) * | 2014-04-25 | 2014-08-06 | 深圳雅臣生物科技有限公司 | 纳米脂质体抗幽门螺杆菌和幽门球菌以及其相关酶和黏附素复合IgY的制备方法及其制剂 |
CN106480003A (zh) * | 2016-10-31 | 2017-03-08 | 中国人民解放军第三军医大学 | 基于cd4+t细胞免疫的幽门螺杆菌优势抗原组合及筛选方法 |
CN110662757A (zh) * | 2017-02-24 | 2020-01-07 | 比奥托梅私人有限公司 | 新型肽及其在诊断中的应用 |
CN111228481A (zh) * | 2018-11-28 | 2020-06-05 | 万华普曼生物工程有限公司 | 一种用于治疗幽门螺旋杆菌的鸡IgY双功能抗体 |
CN113144182A (zh) * | 2021-04-22 | 2021-07-23 | 成都亿妙生物科技有限公司 | 一种幽门螺杆菌口服缓释疫苗及其制备与应用 |
CN117362398A (zh) * | 2023-09-12 | 2024-01-09 | 河北医科大学第一医院 | 抑制幽门螺杆菌摄取金属离子的多肽抗原及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101863964A (zh) * | 2010-05-21 | 2010-10-20 | 中国人民解放军军事医学科学院生物工程研究所 | 一种幽门螺杆菌尿素酶b抗原表位多肽及其应用 |
-
2011
- 2011-07-06 CN CN201110188650.XA patent/CN102260322B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101863964A (zh) * | 2010-05-21 | 2010-10-20 | 中国人民解放军军事医学科学院生物工程研究所 | 一种幽门螺杆菌尿素酶b抗原表位多肽及其应用 |
Non-Patent Citations (3)
Title |
---|
HIROTA K ET AL: "Identification of an antigenic epitope in Helicobacter pylori urease that induces neutralizing antibody production", 《INFECT IMMUN》, vol. 69, no. 11, 30 November 2001 (2001-11-30), pages 6597 - 6603, XP007912653, DOI: doi:10.1128/IAI.69.11.6597?6603.2001 * |
毛旭虎等: "幽门螺杆菌表位疫苗的设计、构建、表达及其免疫原性研究", 《免疫学杂志》, vol. 22, no. 4, 31 July 2006 (2006-07-31) * |
翁康生等: "幽门螺杆菌ureA、ureB基因克隆、序列分析及在E.coli中表达", 《疾病控制杂志》, vol. 6, no. 4, 31 December 2002 (2002-12-31), pages 297 - 300 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103961704A (zh) * | 2014-04-25 | 2014-08-06 | 深圳雅臣生物科技有限公司 | 纳米脂质体抗幽门螺杆菌和幽门球菌以及其相关酶和黏附素复合IgY的制备方法及其制剂 |
CN106480003A (zh) * | 2016-10-31 | 2017-03-08 | 中国人民解放军第三军医大学 | 基于cd4+t细胞免疫的幽门螺杆菌优势抗原组合及筛选方法 |
CN106480003B (zh) * | 2016-10-31 | 2019-09-10 | 中国人民解放军第三军医大学 | 基于cd4+t细胞免疫的幽门螺杆菌优势抗原组合及筛选方法 |
CN110662757A (zh) * | 2017-02-24 | 2020-01-07 | 比奥托梅私人有限公司 | 新型肽及其在诊断中的应用 |
CN111228481A (zh) * | 2018-11-28 | 2020-06-05 | 万华普曼生物工程有限公司 | 一种用于治疗幽门螺旋杆菌的鸡IgY双功能抗体 |
CN113144182A (zh) * | 2021-04-22 | 2021-07-23 | 成都亿妙生物科技有限公司 | 一种幽门螺杆菌口服缓释疫苗及其制备与应用 |
CN113144182B (zh) * | 2021-04-22 | 2023-03-10 | 成都欧林生物科技股份有限公司 | 一种幽门螺杆菌口服缓释疫苗及其制备与应用 |
CN117362398A (zh) * | 2023-09-12 | 2024-01-09 | 河北医科大学第一医院 | 抑制幽门螺杆菌摄取金属离子的多肽抗原及其应用 |
CN117362398B (zh) * | 2023-09-12 | 2024-03-19 | 河北医科大学第一医院 | 抑制幽门螺杆菌摄取金属离子的多肽抗原及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102260322B (zh) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3418171B2 (ja) | モノクローナル抗体la2 | |
CN102260322B (zh) | 幽门螺杆菌抗原肽及其应用 | |
CN107033250B (zh) | 牛冠状病毒重组多表位抗原及其应用 | |
AU2006212602A1 (en) | Surface-located streptococcus pneumoniae polypeptides | |
CN1062605C (zh) | 大肠杆菌疫苗的制备方法 | |
JPH04504656A (ja) | ボルデテラワクチン | |
JP2003527100A (ja) | タンパク質 | |
CN102004150A (zh) | 基于重组ul51蛋白的鸭瘟病毒抗体的检测方法 | |
CN103724413B (zh) | 旋毛虫副肌球蛋白b细胞抗原表位8a1及其应用 | |
WO2008119358A2 (en) | Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions | |
US20070178110A1 (en) | Surface-located campylobacter jejuni polypeptides | |
US5911996A (en) | 43 Kd protein vaccine and method for the production thereof | |
CN105777909A (zh) | 一种猪趋化因子介导的a型口蹄疫靶向性复合表位蛋白及疫苗 | |
CN113512098B (zh) | 鉴别猪瘟病毒和牛病毒性腹泻病毒血清抗体间接elisa方法及其应用 | |
CN111378628B (zh) | 一种分泌结核分枝杆菌esat6蛋白特异性抗体的杂交瘤细胞株、其抗体及应用 | |
CN107033224B (zh) | 一种口蹄疫病毒灭活抗原纯化浓缩方法 | |
CN104096228B (zh) | 一种增强流行性嗜血杆菌b型多糖蛋白结合物免疫原性的方法 | |
CN104096224B (zh) | 一种增强流行性嗜血杆菌b型多糖蛋白结合物免疫原性的方法 | |
CN117886891B (zh) | 靶向巨噬细胞cd169受体的多肽及其应用 | |
CN115340997B (zh) | 一种基于Lpp引导序列靶向呈递和高效表达外源抗原的重组沙门菌构建方法 | |
CN116731128A (zh) | 一种副猪嗜血杆菌基因II型Omp P2蛋白的特异性B细胞线性表位及其应用 | |
CN118185881A (zh) | 一种非洲猪瘟的单克隆抗体及抗原表位 | |
CN116751307A (zh) | 大肠杆菌多表位嵌合蛋白及其应用 | |
CN116655747A (zh) | ASFV p49蛋白线性表位肽、其特异抗体、杂交瘤细胞及其应用 | |
CN113683665A (zh) | 一种圆圈病毒3型卵黄抗体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN JINBAIHUI BIOLOGIC CO., LTD. Free format text: FORMER OWNER: SU JING Effective date: 20140421 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 518067 SHENZHEN, GUANGDONG PROVINCE TO: 518055 SHENZHEN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140421 Address after: 518055, Shenzhen, Guangdong, Nanshan District province Taoyuan street, Tian Lao industrial A District 9, west of the two floor Patentee after: SHENZHEN GENEBIOHEALTH CO., LTD. Address before: 3, 518067 5A, phase 1, Shekou Garden City, Shenzhen, Guangdong, Nanshan District Patentee before: Su Jing |